IDEXX Laboratories Inc (IDXX)
IDEXX Laboratories Inc (IDXX) carries a ŷRobot AI score of 71 out of 100. The model's fair value estimate is $554.29, 9.4% above the last close of $506.67. The chart signal reads Hold.
| Metric | IDXX |
|---|---|
| AI score | 71 / 100 |
| Chart signal | Hold |
| Fair value estimate | $554.29 |
| Upside to fair value | 9.4% |
| Previous close | $506.67 |
| P/E | 37.14 |
| Price / sales | 8.96 |
| Market cap | $40.60B |
| EPS | 13.94 |
| Revenue growth | 8.0% |
| 1-year price change | -4.6% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about IDXX
Is IDXX overvalued or undervalued right now?
As of Oct 7, 2026, ŷRobot's fair-value model estimates IDEXX Laboratories Inc (IDXX) at $554.29 against a last close of $506.67, implying 9.4% upside to the model's estimate.
Is IDXX's chart signal bullish or bearish?
The chart-signal model classifies IDXX as Neutral as of Oct 7, 2026, with a signal score of 0.11 on a -1 to 1 scale.
What is IDXX's ŷRobot AI score?
IDXX scores 71 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 7, 2026.
Is IDXX stock expensive on P/E and P/S?
IDXX trades at 37.1 times earnings and 9.0 times sales as of Oct 7, 2026.
What does IDXX's seasonal forecast show?
ŷRobot's seasonal forecast curve for IDXX reads -0.8% at 30 days, -1.5% at 90 days, and -4.6% at one year as of Oct 7, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is IDXX growing?
IDEXX Laboratories Inc's revenue growth is +8.0% and free-cash-flow growth is +8.4% on the latest reported figures.
IDXX chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.